Physician profile
Donna Schultz
NPI 1922427640
$3,172.65
in general payments reported to CMS, 2019-2025
12 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $34.73 · 2023: $1,921 · 2024: $990 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,596 · Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,595.61 |
| Food and Beverage | $1,429.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $2,186.20 | 2023-2025 | Puraply, Puraply Wound Matrix, Apligraf |
| Reapplix INC. | $497.53 | 2024 | 3c Patch Kit - Box |
| Kerecis Limited | $160.36 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Sobi, INC | $112.84 | 2021 | |
| Smith+Nephew, INC. | $66.68 | 2022-2023 | Collagenase Santyl, Regranex |
| Mimedx Group, INC. | $48.81 | 2025 | |
| Kci USA, INC. | $21.47 | 2023 | Activ.A.C. |
| Glaxosmithkline, LLC. | $18.25 | 2025 | Bexsero, Rotarix |
| Next Science LLC | $15.93 | 2024 | Xperience, Blastx, Surgx |
| Paratek Pharmaceuticals, INC. | $15.47 | 2023 | Nuzyra |
| Solventum Corporation | $15.42 | 2025 | Promogran Prisma, V.A.C.Ulta, 3m Cavilon |
| Integra Lifesciences Corporation | $13.69 | 2023 | Tcc-Ez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.